Study Name | Indication | Description | Location | Stipend | Apply |
---|---|---|---|---|---|
Abbvie M16-852 | Giant Cell Arteritis | A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis | Vandalia, Ohio | $1900 | Apply |
CA41705 | Lupus Nephritis | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS | Vandalia, Ohio | $1892 | Apply |
AFFINITY (PSA2003) | Psoriatic Arthritis | A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | Vandalia, Ohio | $936 | Apply |
SOLSTICE (PSA3005) | Psoriatic Arthritis | A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis who had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor [alpha] Agent | Vandalia, Ohio | $1300 | Apply |
STAR (PSA4002) | Psoriatic Arthritis | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease | Vandalia, Ohio | $1300 | Apply |
ACTIV-2 | COVID-19 | Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID) | Springboro, Ohio | $730 | Apply |
PSA-013 | Psoriatic Arthritis | Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. | Springboro, Ohio | $500 | Apply |